Cara touts subgroup in failed atopic dermatitis trial, but stock craters
Cara Therapeutics will join the growing list of biotech to launch a Phase III despite failing Phase II.
The itch-focused company announced Thursday that its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
